QLC5508 clinical trials
Also written QLC5508.
How each study uses QLC5508 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the QLC5508 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test QLC5508.
- Dec 2026Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug InteractionPhase 1 · Qilu Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses QLC5508 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung CancerRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07802821Written as QLC5508
- QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine CarcinomaNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07894211Written as QLC5508
- Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug InteractionRecruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07620041Written as QLC5508 (Investigational Product / Formulation T)
- QLC5508 in Participants With Metastatic Prostate CancerNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07632690Written as QLC5508
- QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell CarcinomaRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07463573Written as QLC5508
- A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07256782Written as QLC5508
Given beside what is tested · 1 — QLC5508 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.